Table 8.
Change of LEDD and medication-induced complications in patients in previous studies of bilateral subthalamic nucleus stimulation in PD.
| Study | % of Change of LEDD | % of Change of Dyskinesia | % of Change of Motor Fluctuation |
|---|---|---|---|
| Limousin et al. [58] | * | −60% | * |
| Ostergaard et al. [59] | −19.5% | −86% | −79% |
| Simuni et al. [62] | −55% | −64.3% | −32.4% |
| Thobois et al. [64] | −65.5% | −76% | * |
| Vesper et al. [60] | −53% | −71.9% | −35% |
| Vingerhoets et al. [63] | −79% | −92% | −95% |
| Volkmann et al. [65] | −65.3% | −83.3% | * |
| Herzog et al. [61] | −67% | −85% | * |
| Krause et al. [66] | −30% | −70% | −16% |
| Fraix et al. [67] | −80.7% | −86.7% | * |
| Kleiner-Fisman et al. [68] | −42% | −65.5% | −58% |
| Krack et al. [69] | −63% | −65% | * |
| Romito et al. [70] | −56.2% | −83.9% | −94.2% |
| Visser-Vandewalle et al. [71] | −47.2% | −79% | −78.4% |
| Rodrguez-Oroz et al. [72] | −50.0% | −53% | * |
| Rodrguez-Oroz et al. [73] | −35% | −59% | * |
| Wider et al. [74] | −56.9% | −85.4% | −84.2% |
| Gervais-Bernard et al. [75] | −54.4% | −60% | * |
| Castrioto et al. [26] | −36.3% | −68.8% | −46.9% |
| Weaver et al. [76] | −35.7% | −75% | * |
| Tabbal et al. [78] | 45% | * | * |
| This study | −54.1% | −65.1% | −48.6% |
LEDD levodopa equivalent daily dose; PD: Parkinson’s disease, UPDRS: Unified Parkinson’s Disease Rating Scale, %: percentage, *: no available data.